Sutro Biopharma, Inc.
STRO
$20.48
-$0.83-3.90%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 13.45% | 37.36% | 15.99% | -74.88% | -67.70% |
| Total Depreciation and Amortization | -18.79% | -8.90% | 1.47% | 6.88% | 6.35% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 45.31% | 99.53% | 187.48% | 610.66% | 21.37% |
| Change in Net Operating Assets | 74.10% | -455.50% | -666.28% | -2,418.70% | -693.43% |
| Cash from Operations | 41.67% | 22.13% | 7.47% | -110.47% | -233.08% |
| Capital Expenditure | 85.87% | 86.10% | 45.29% | 25.70% | -6.23% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -85.18% | -88.35% | -78.92% | 4.87% | 248.68% |
| Cash from Investing | -85.17% | -88.41% | -79.40% | 5.85% | 243.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 100.00% | 100.00% |
| Issuance of Common Stock | 7,631.11% | 5.62% | -99.62% | -99.62% | -98.64% |
| Repurchase of Common Stock | -98.22% | 0.95% | 34.77% | 40.41% | 23.87% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 10,179.78% | 5.64% | -99.95% | -99.91% | -98.81% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 63.79% | -179.36% | -209.21% | -217.17% | 81.46% |